Eyenovia receives patent for piezo-print technology features

Eyenovia Inc. has announced that two additional patent applications have received Notices of Allowance from the U.S. Patent and Trademark Office.

“We are pleased that the USPTO continues to recognize the novel features of our piezo-print technology that has the ability to gently and efficiently deliver micro-therapeutic solutions to the eye,” Sean Ianchulev, MD, CEO and chief medical officer for Eyenovia, said in a press release.

The new patents cover physiologic microdroplet ejection diameters and velocities, which, Eyenovia said, can enable a quicker delivery of ophthalmic therapeutics to the eye. According to the release, the technology reaches a velocity that can, “beat the eye’s blink reflex.”

The two new patents will join eight U.S. and 27 international patents issued and allowed as part of Eyenovia’s existing intellectual property portfolio.

“With an expanding global intellectual property portfolio, we look forward to advancing our late-stage clinical assets for mydriasis, glaucoma and myopia into phase 3 development,” Ianchulev said in the release.

Eyenovia Inc. has announced that two additional patent applications have received Notices of Allowance from the U.S. Patent and Trademark Office.

“We are pleased that the USPTO continues to recognize the novel features of our piezo-print technology that has the ability to gently and efficiently deliver micro-therapeutic solutions to the eye,” Sean Ianchulev, MD, CEO and chief medical officer for Eyenovia, said in a press release.

The new patents cover physiologic microdroplet ejection diameters and velocities, which, Eyenovia said, can enable a quicker delivery of ophthalmic therapeutics to the eye. According to the release, the technology reaches a velocity that can, “beat the eye’s blink reflex.”

The two new patents will join eight U.S. and 27 international patents issued and allowed as part of Eyenovia’s existing intellectual property portfolio.

“With an expanding global intellectual property portfolio, we look forward to advancing our late-stage clinical assets for mydriasis, glaucoma and myopia into phase 3 development,” Ianchulev said in the release.